Pulmonx Corp
NASDAQ:LUNG
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
US |
Pulmonx Corp
NASDAQ:LUNG
|
369.9m USD | -10.1 | ||
JP |
Hoya Corp
TSE:7741
|
6.4T JPY | 31.1 | ||
CH |
Alcon AG
SIX:ALC
|
36.1B CHF | 28.7 | ||
DK |
Coloplast A/S
CSE:COLO B
|
189.1B DKK | 34.2 | ||
US |
Align Technology Inc
NASDAQ:ALGN
|
20.2B USD | 25.7 | ||
US |
Cooper Companies Inc
NYSE:COO
|
18.4B USD | 32.5 | ||
KR |
H
|
HLB Inc
KOSDAQ:028300
|
13.9T KRW | -124.4 | |
CN |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
61.5B CNY | 43.4 | ||
UK |
ConvaTec Group PLC
LSE:CTEC
|
5.3B GBP | 18.1 | ||
US |
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
5.8B USD | 13.7 | ||
US |
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.3B USD | 16.1 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.